Why This MindMed Analyst Is Bullish: ‘One Of The Most Diverse Pipelines In Psychedelics’
Mind Medicine (MindMed) Inc (NASDAQ: MNMD) shares traded higher by 3.3% on Monday after one analyst initiated bullish coverage of the psychedelics stock.
The Analyst: Maxim analyst Jason McCarthy initiated coverage of MindMed with a Buy rating and $6 price target.